177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems

Fani, M; Bouziotis, P; Harris, AL; Psimadas, D; Gourni, E; Loudos, G; Varvarigou, AD; Maecke, HR

dc.contributor.author	Fani, M	en
dc.contributor.author	Bouziotis, P	en
dc.contributor.author	Harris, AL	en
dc.contributor.author	Psimadas, D	en
dc.contributor.author	Gourni, E	en
dc.contributor.author	Loudos, G	en
dc.contributor.author	Varvarigou, AD	en
dc.contributor.author	Maecke, HR	en
dc.date.accessioned	2014-03-01T01:26:33Z
dc.date.available	2014-03-01T01:26:33Z
dc.date.issued	2007	en
dc.identifier.issn	0033-8230	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/18133
dc.subject	Angiogenesis	en
dc.subject	DOTA	en
dc.subject	DTPA	en
dc.subject	Lutetium-177	en
dc.subject	Monoclonal antibodies	en
dc.subject	VEGF	en
dc.subject.classification	Chemistry, Inorganic & Nuclear	en
dc.subject.classification	Nuclear Science & Technology	en
dc.subject.other	ENDOTHELIAL GROWTH-FACTOR	en
dc.subject.other	CANCER-THERAPY	en
dc.subject.other	NUDE-MICE	en
dc.subject.other	RADIOIMMUNOTHERAPY	en
dc.subject.other	BIODISTRIBUTION	en
dc.subject.other	VEGF	en
dc.subject.other	Y-90	en
dc.subject.other	BEVACIZUMAB	en
dc.subject.other	INHIBITION	en
dc.subject.other	STABILITY	en
dc.title	177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems	en
heal.type	journalArticle	en
heal.identifier.primary	10.1524/ract.2007.95.6.351	en
heal.identifier.secondary	http://dx.doi.org/10.1524/ract.2007.95.6.351	en
heal.language	English	en
heal.publicationDate	2007	en
heal.abstract	Vascular Endothelial Growth Factor (VEGF) is one of the molecules which regulate angiogenesis, a phenomenon observed in many diseases, including cancer. VG76e, an anti-VEGF monoclonal antibody, was labeled with 177Lu via p-SCN-Bz-DOTA and CHX-A″-DTPA chelating systems, in order to investigate its possible therapeutic use. Labeling was performed by a 30 min incubation of 177LuCl3 and each immunoconjugate, at 37°C. Radiochemical analysis showed the formation of a single radioactive species, at a yield higher than 98%, for both immunoconjugates. Kits have been formulated for both VG76e-DOTA and VG76e-DTPA. Stability studies, in the presence of a competitor excess, showed that both radiolabeled species remained sufficiently stable (95%) for at least 48 h. Biodistribution results in normal mice were similar for both radioimmunoconjugates, with no significant bone uptake. Gamma camera images of tumor-bearing mice showed satisfactory visualization of the tumor 24 h p.i., while a higher uptake was observed at 48 h p.i. Our findings indicate that both the bifunctional chelating agents p-SCN-Bz-DOTA and CHX-A″-DTPA can be used for the labeling of VG76e with 177Lu, with high labeling yield and stability. Their in vivo behaviour in normal and tumor-bearing mice looks promising and they can be successfully used for tumor imaging studies. © by Oldenbourg Wissenschaftsverlag.	en
heal.publisher	OLDENBOURG VERLAG	en
heal.journalName	Radiochimica Acta	en
dc.identifier.doi	10.1524/ract.2007.95.6.351	en
dc.identifier.isi	ISI:000247310700008	en
dc.identifier.volume	95	en
dc.identifier.issue	6	en
dc.identifier.spage	351	en
dc.identifier.epage	357	en